PM-359

N/A

Report date: 2025/07/30 13:53:51

Base Information

Drug NamePM-359

Drug Alias NamePM359PM-359

ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapyCell and gene therapy > Gene therapy > Gene editing +[4]

Mechanisms of ActionNeutrophil cytosol factor 1 gene transference

TargetsNeutrophil cytosol factor 1

Therapy Area/IndicationsGranulomatous Disease, Chronic

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCanadaUnited StatesUnited Kingdom

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesPrime Medicine Inc

China Registration ClassN/A

Develop Information

Active CompaniesPrime Medicine Inc

Inactive CompaniesN/A

Active IndicationsGranulomatous Disease, Chronic

Inactive IndicationsN/A

Other Information

ATC CodeN/A